Pharmaceuticals APAC News & Press Release Distribution

Pharmaceuticals

All
Global

Antengene to Present Results from Three Programs at the 2024 SITC Annual Meeting

SHANGHAI and HONG KONG, Oct. 5, 2024 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for cance...

2024-10-07 13:14 1772

Clarivate in partnership with Abiquifi Announces Annual Summit LATAM Agenda

Top industry leaders to explore AI, data, strategic partnerships, and innovation opportunities inLatin America at premier Life Sciences event LONDON, Oct. 4, 2024 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT) a leading global provider of transformative intelligence, today announced the full agenda ...

2024-10-04 15:00 1776

Sirnaomics Has Been Subscribed for 17,527,696 Subscription Shares, New Capital Injection to Promote Business Growth and Development

HONG KONG, GERMANTOWN, Md., and SUZHOU, China,, Oct. 4, 2024 /PRNewswire/ -- Sirnaomics Ltd. (the "Company", together with its subsidiaries, the "Group" or " Sirnaomics"; stock code: 2257.HK), a leading biopharmaceutical company engaged in the discovery and development of advanced RNAi therapeutic...

2024-10-04 13:03 5503

ABL Bio Announces Clinical Collaboration to Evaluate ABL103 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Solid Tumors

- MSD will supply KEYTRUDA to be evaluated in combination with ABL Bio's ABL103 in a Phase1b/2 clinical trial SEONGNAM, South Korea, Oct. 4, 2024 /PRNewswire/ -- ABL Bio (CEO Sang Hoon Lee ), a company specializing in bispecific antibodies, today announced that it has entered into a clinical tria...

2024-10-04 12:40 2337

First Patient Dosed in Phase II 'CA-NINE' Trial of TLX250-CDx for Detection of Recurrent Kidney Cancer After Surgery

MELBOURNE, Australia, Oct. 4, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the first patient has been dosed in a Phase II trial exploring the clinical utility of Telix's first-in-class investigational PET[1] agent, TLX250-CDx (89Zr-girentu...

2024-10-04 04:00 2831

IBC launches RadSep, Inc.: Best-in-class, highly selective separations using Molecular Recognition Technology™ (MRT™) for production of critical radioisotopes essential to cancer therapies

* Best-in-class, highly selective separations technology for the radiopharmaceuticals industry * Exhibitor at the European Association of Nuclear Medicine (EANM) Congress in Hamburg, Germany 20-23 October 2024 at Booth S14 (Exhibition Hall 3) * Over 36 years of experience with first generatio...

2024-10-03 22:15 1717

Hetero Signs Voluntary Licensing Agreement with Gilead to Transform Global HIV response, Expanding Access to Groundbreaking Lenacapavir to 120 high-incidence countries

- Non-exclusive voluntary license agreement enables the manufacture and distribution of lenacapavir for HIV prevention and treatment of heavily treatment-experienced patients with multi drug-resistant HIV HYDERABAD, India, Oct. 2, 2024 /PRNewswire/ -- Hetero, India's leading pharmaceutical comp...

2024-10-02 22:53 2493

OPTEL and Worximity Join Forces to Boost Line Performance with Real-Time OEE Solutions

QUÉBEC CITY, Oct. 1, 2024 /PRNewswire/ -- OPTEL, a global leader in traceability and vision systems, and Worximity, a leading provider of OEE and real-time production monitoring, are partnering to help manufacturers boost operational efficiency.

2024-10-01 19:00 1057

OPTEL and Worximity Join Forces to Boost Line Performance with Real-Time OEE Solutions

Frost & Sullivan co-published Recombinant Type III Triple-Helix Collagen Whitepaper with Everon Healthcare

SHANGHAI, Oct. 1, 2024 /PRNewswire/ -- Frost & Sullivan and Everon Healthcare have conducted extensive investigation across the recombinant collagen Industry and co-published the "Recombinant Type III Triple-Helix Collagen Whitepaper" on Sep. 29th, 2024, which aims to analyze the latest research a...

2024-10-01 17:28 1818

TraceLink Releases Amadeus, the First Generative AI Assistant for Accelerating the Digitalization of Supply Networks on the Opus Platform

Trained on a rich set of information from a unified content repository, Opus Orchestration Architects, Solution Designers, Network Administrators, and those simply interested in learning more about TraceLink's solutions are empowered with information in seconds BOSTON, Oct. 1, 2024 /PRNewswire/ ...

2024-10-01 16:00 1361

Great Place To Work® Australia and New Zealand names 15 Best Workplaces in Healthcare, Biopharma & Social Assistance in 2024

SYDNEY, Oct. 1, 2024 /PRNewswire/ -- Great Place To Work® ANZ, the global authority on workplace culture today announces theirinaugural 15 Best Workplaces™ in Healthcare, Social Assistance and BioPharma in 2024. The companies are announced across two lists: Best Workplaces in Biotechnology a...

2024-10-01 07:00 8032

Alphamab Oncology and CSPC Achieved a Licensing Agreement on Anti-HER2 Bispecific ADC JSKN003 in Mainland China

SUZHOU, China, Sept. 30, 2024 /PRNewswire/ -- Alphamab Oncology (stock code: 9966 HK) announced that Jiangsu Alphamab Biopharmaceuticals Co., Ltd. ("Alphamab"), a wholly-owned subsidiary of Alphamab Oncology ("the Company"), entered into a licensing agreement (the "Licensing Agreement") on anti-H...

2024-09-30 10:35 3222

Multiple Study Results of Kelun-Biotech's TROP2-ADC SKB264 (sac-TMT) at 2024 CSCO Congress

CHENGDU, China, Sept. 29, 2024 /PRNewswire/ -- From September 25th to 29th, the 27th China Clinical Oncology Congress and the 2024 CSCO Annual Meeting were held inXiamen. Experts and scholars in the field of oncology from all over China gathered together to discuss the hotspots at the forefront o...

2024-09-29 11:52 2537

Multiple Study Results of Kelun-Biotech's TROP2-ADC SKB264 (sac-TMT) at 2024 CSCO Congress

Frost & Sullivan Released Report: "2024 Blue Book on Chinese Biopharmaceuticals Going Global: Current Status and Trends"

SHANGHAI, Sept. 28, 2024 /PRNewswire/ -- Frost & Sullivan released the "2024 Blue Book on Chinese Biopharmaceuticals Going Global: Current Status and Trends" which focus on the progress of Chinese biopharmaceuticals going global and analyzes the driving forces behind their accelerated global expa...

2024-09-28 09:11 3230

LakeShore Biopharma Announces Results of Extraordinary General Meeting on Share Consolidation

GAITHERSBURG, Md., Sept. 27, 2024 /PRNewswire/ -- LakeShore Biopharma Co., Ltd (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for ...

2024-09-27 19:00 1482

Anbogen Announces Drug Supply Collaboration with BeiGene to Evaluate Combination Therapy in Colorectal Cancer

TAIPEI, Sept. 27, 2024 /PRNewswire/ -- Anbogen, a clinical-stage biotech company, today announced a drug supply collaboration to evaluate the combination of Anbogen's HDAC inhibitor, ABT-301, with BeiGene's anti-PD-1 antibody tislelizumab, in patients with mismatch repair–proficient (pMMR) or mi...

2024-09-27 16:00 1537

ArkBio Announces Publication of Phase 3 Clinical Trial Results of Ziresovir for the Treatment of RSV Infection in The New England Journal of Medicine

SHANGHAI, Sept. 26, 2024 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio"), a clinical stage biopharmaceutical company focused on the development of therapeutics in respiratory, infectious and pediatric diseases, announced that the results of the phase 3 clinical trial of zireso...

2024-09-26 20:28 1809

Innovent Announces NMPA Acceptance of NDA for Picankibart (Anti-IL-23p19 Antibody) for Treating Moderate to Severe Plaque Psoriasis

SAN FRANCISCO and SUZHOU, China, Sept. 26, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metaboli...

2024-09-26 12:15 1827

Rx-360 Announces Approval as a Pilot Center of Excellence for the APEC Regulatory Harmonization Steering Committee

PHILADELPHIA, Sept. 25, 2024 /PRNewswire/ -- Rx-360® is pleased to announce that it has been accepted as a Pilot Center of Excellence (CoE) for the APEC Regulatory Harmonization Steering Committee. The pilot will be focused on the Global Medical Product Supply Chain Integrity Priority Work Area R...

2024-09-25 21:09 1550

GSK's Arexvy is a vaccine approved to protect older adults from respiratory syncytial virus (RSV) disease in Malaysia

* Adults aged 60 and over with underlying co-morbidities are at high risk of developing severe infections from RSV * Vaccine showed 82.6% overall vaccine efficacy against RSV-LRTD with 94.6% efficacy observed in adults with co-morbidities vii KUALA LUMPUR, Malaysia, Sept. 25, 2024 /PRNewswire...

2024-09-25 16:45 1528

GSK's Arexvy is a vaccine approved to protect older adults from respiratory syncytial virus (RSV) disease in Malaysia

1 2 3 456 7 8 ... 187